Published on

Clinical Toxicology — North American Coral Snakebite

1. Overview

North American coral snakes are venomous snakes belonging to the family Elapidae, which also includes cobras, mambas, and kraits.

Coral snake envenomation is uncommon in the United States but potentially life-threatening because venom can impair neuromuscular transmission and produce progressive respiratory paralysis.

Unlike rattlesnake and other pit viper envenomations, coral snakebites often cause little pain, swelling, or visible tissue injury.

The most important clinical hazard is delayed neurotoxicity after an initially reassuring examination.

Modern management emphasizes:

  • Prompt emergency evaluation after every credible bite.
  • Careful species identification.
  • Repeated neurologic, bulbar, and respiratory examinations.
  • Early preparation for airway management.
  • Timely access to species-appropriate antivenom.
  • Avoidance of unnecessary prophylactic antivenom in asymptomatic patients.

The historical recommendation to administer antivenom after every confirmed Eastern or Texas coral snakebite has changed. Current U.S. labeling and observational evidence favor monitored observation, with antivenom administered when clinically important envenomation develops.

2. North American coral snake species

Three native coral snake species are recognized in the United States.

Eastern coral snake

Scientific name: Micrurus fulvius.

Found in Florida and other areas of the southeastern United States.

The Eastern coral snake is responsible for the most clinically important North American coral snake neurotoxicity.

Severe envenomation can produce cranial nerve dysfunction, generalized weakness, and respiratory paralysis.

Texas coral snake

Scientific name: Micrurus tener.

Found primarily in Texas and adjoining areas of the south-central United States and Mexico.

The older classification Micrurus fulvius tenere has been replaced by recognition of M. tener as a separate species.

Texas coral snake venom is neurotoxic, but most documented U.S. bites cause local pain or paresthesias without severe paralysis.

This distinction does not mean all Texas coral snakebites are harmless.

Sonoran or Arizona coral snake

Scientific name: Micruroides euryxanthus.

Found in parts of Arizona, New Mexico, and northern Mexico.

Most reported bites cause limited symptoms.

Serious systemic neurotoxicity is uncommon, but exposure should still be evaluated according to the species identification and clinical presentation.

Important antivenom distinction

North American Coral Snake Antivenin is intended for envenomation caused by Eastern and Texas coral snakes.

It does not neutralize Sonoran coral snake venom in experimental cross-neutralization testing.

3. Snake identification

North American coral snakes are often recognized by their red, yellow or pale, and black bands.

However, several nonvenomous snakes possess superficially similar coloration.

The color-band rhyme

The historical rule:

“Red touches yellow, kills a fellow; red touches black, venom lack.”

should not be used to exclude a venomous snakebite.

Why the rhyme is unreliable

Color patterns vary between species and individual snakes.

Some snakes have atypical pigmentation.

The rule is particularly unreliable outside the United States, where numerous venomous coral snake species have different band arrangements.

Photographs taken under poor lighting may also be misleading.

Recommended identification

Identification should rely on:

  • The geographical location.
  • A clear photograph obtained without approaching the snake.
  • Expert herpetologic identification.
  • Reliable information about a known captive specimen.

Important warning

Do not attempt to catch, handle, or kill a snake for identification.

Even a recently killed snake may cause an additional envenomation through reflexive biting.

4. Fang structure and venom delivery

Coral snakes possess relatively short, fixed front fangs.

A bite may leave very small punctures or scratches.

Visible fang marks can be difficult to identify or completely absent.

Does the snake need to chew?

Coral snakes sometimes hold on to the bitten area and make repeated jaw movements.

Prolonged attachment may increase the likelihood of venom delivery.

However, a brief strike can still produce clinically important envenomation.

The historical suggestion that prolonged chewing is required should therefore be removed.

Dry bites

A bite may occur without significant venom injection.

However, neither fang-mark appearance nor the absence of immediate symptoms reliably establishes a dry bite.

5. Venom composition and mechanism

North American coral snake venom contains several families of biologically active toxins.

Two important groups are:

Three-finger toxins: Certain members bind to nicotinic acetylcholine receptors at the neuromuscular junction.

Phospholipase A₂ neurotoxins: Certain components impair neurotransmission through effects on motor nerve terminals.

Postsynaptic neurotoxicity

Postsynaptic toxins interfere with acetylcholine receptor activity.

This prevents normal transmission of nerve impulses to skeletal muscle.

Such effects can be potentially reversible.

Presynaptic neurotoxicity

Presynaptic toxins may damage motor nerve terminals and reduce acetylcholine release.

Recovery from established injury can require regeneration of affected nerve-terminal structures.

Clinical implications

Neuromuscular impairment can progress to respiratory failure.

Antivenom neutralizes susceptible circulating venom components but may not reverse nerve-terminal damage that has already occurred.

Correction to the historical chapter

Coral snake venom does not produce only irreversible neuromuscular blockade.

Both presynaptic and postsynaptic mechanisms are involved, and their relative contributions influence the clinical course.

6. Toxic dose and risk factors

A single bite can potentially produce fatal envenomation.

No clinically useful minimum toxic dose can be calculated from the number of puncture wounds or duration of contact.

Factors affecting severity

Important factors include:

  • Snake species.
  • Quantity of venom delivered.
  • Bite circumstances.
  • Patient size.
  • Time to medical assessment.
  • Ability to provide respiratory support.
  • Availability of antivenom.

Children

Children may be at increased risk of severe effects relative to the quantity of venom injected.

Nevertheless, significant respiratory paralysis can also occur in adults.

Location of the bite

Hands and fingers are common bite sites because many exposures involve deliberate handling.

However, bites can also occur accidentally to the feet or other exposed areas.

The location of the bite does not reliably predict severity.

7. Clinical manifestations

Local symptoms

The bite may cause:

  • Mild pain.
  • Tingling.
  • Numbness.
  • Local tenderness.
  • Mild redness or swelling.

Substantial tissue destruction is not characteristic of typical Eastern coral snake envenomation.

Early systemic symptoms

Possible early manifestations include nausea, vomiting, headache, dizziness, sweating, and more widespread paresthesias.

These symptoms are nonspecific but deserve attention after a credible bite.

Cranial nerve dysfunction

Important findings include:

  • Ptosis.
  • Diplopia.
  • Impaired eye movements.
  • Facial weakness.
  • Slurred speech.
  • Tongue weakness or fasciculations.

Bulbar dysfunction

Patients may develop:

  • Difficulty swallowing.
  • Weak cough.
  • Abnormal speech.
  • Difficulty handling saliva.
  • Choking or aspiration.

New bulbar symptoms are warning signs of potentially progressive neuromuscular paralysis.

Generalized weakness

Weakness may extend to the neck, limbs, diaphragm, and other respiratory muscles.

Respiratory failure

Progressive neuromuscular impairment can lead to hypoventilation and respiratory arrest.

A patient may remain conscious despite severe weakness.

Unusual findings

Seizures, profound altered consciousness, and major coagulation abnormalities are not characteristic of uncomplicated North American coral snake envenomation.

Their presence should prompt evaluation for another or additional cause.

8. Delayed onset

Clinical manifestations may not develop immediately.

After Eastern coral snake envenomation, neurologic symptoms may emerge several hours after the bite.

Historical case reports describe onset delayed by approximately 12 hours, followed by rapid deterioration.

Why delayed toxicity matters

Patients may feel well and have normal vital signs shortly after envenomation.

Local findings may remain insignificant even as systemic neurotoxicity develops.

Clinical principle

A normal initial examination cannot exclude potentially serious coral snake envenomation.

Observation must be long enough to detect evolving neurologic toxicity.

9. First aid

Immediate actions

Call emergency medical services.

Advise the patient to remain calm and avoid unnecessary movement.

Rest and immobilize the bitten extremity in a comfortable position.

Remove rings, watches, and other constricting items.

Wound care

Clean the area gently with soap and water when practical.

Cover the wound with a clean dressing.

Do not delay emergency transportation.

Treatments to avoid

Do not:

  • Apply a tight tourniquet.
  • Cut or incise the wound.
  • Attempt to suck out venom.
  • Use commercial venom-extraction devices.
  • Apply ice.
  • Apply electrical shocks.
  • Attempt chemical neutralization.

These measures do not provide established clinical benefit and may cause additional injury.

Pressure immobilization

Pressure immobilization has a theoretical role in slowing the spread of some neurotoxic venoms.

However, the 2024 American Heart Association and American Red Cross first-aid guidelines advise against routine pressure immobilization bandaging for snakebites in North America.

Correct application is difficult, and evidence supporting routine use for Eastern coral snakebites is inadequate.

Simple immobilization without constricting pressure is the preferred general first-aid approach.

10. Emergency assessment

Initial priorities

Assess airway, breathing, circulation, mental status, and vital signs.

Identify the snake species when reliable information is available.

Contact a regional poison control center immediately.

History

Determine:

  • Time of the bite.
  • Location and circumstances.
  • Snake identity.
  • Whether the snake remained attached.
  • Symptoms since the bite.
  • First aid already performed.
  • Prior antivenom exposure.
  • History of horse-serum hypersensitivity.

Examination

Perform a baseline assessment of:

  • Cranial nerve function.
  • Eye movements.
  • Eyelid elevation.
  • Speech.
  • Swallowing.
  • Tongue movement.
  • Neck strength.
  • Limb strength.
  • Cough strength.
  • Respiratory rate and effort.

Serial assessments

Repeated examinations are more informative than a single assessment.

In significant or high-risk exposures, reassess neurologic, bulbar, and respiratory findings frequently, often at least hourly during the early monitored period.

11. Respiratory monitoring

Respiratory muscle weakness is the most important life-threatening complication.

Pulse oximetry

Pulse oximetry is useful but has limitations.

Normal oxygen saturation does not exclude early neuromuscular respiratory failure.

Hypoventilation may progress before significant hypoxemia develops.

Supplemental oxygen may further obscure inadequate ventilation.

Capnography

End-tidal carbon dioxide monitoring can help detect inadequate ventilation.

Respiratory muscle measurements

Serial measurements may include:

Forced vital capacity (FVC).

Negative inspiratory force (NIF).

These measurements are useful when the patient can cooperate.

Interpretation

A falling FVC or weakening inspiratory force should prompt urgent reassessment.

Thresholds borrowed from other neuromuscular disorders, such as FVC below approximately 20 mL/kg or NIF weaker than approximately −30 cm H₂O, may help guide airway planning.

However, these numerical thresholds have not been specifically validated for coral snake envenomation.

Clinical deterioration takes precedence over any single measurement.

12. Airway management

Indications

Endotracheal intubation may be required for:

  • Progressive bulbar weakness.
  • Inability to protect the airway.
  • Difficulty controlling secretions.
  • Weak or ineffective cough.
  • Respiratory muscle fatigue.
  • Hypoventilation.
  • Respiratory failure.

Early intervention

Airway management should occur before severe respiratory collapse.

Do not wait for marked hypoxemia or profound hypercapnia when progressive paralysis is evident.

Mechanical ventilation

Severely envenomated patients may require ventilatory support for days.

Antivenom administration does not guarantee immediate reversal of established paralysis.

Important warning

Never delay necessary intubation while waiting for antivenom to arrive.

Supportive ventilation can be lifesaving even when antivenom is unavailable.

13. Laboratory testing

No routine laboratory test confirms or excludes coral snake envenomation.

Uncomplicated bites

Routine laboratory abnormalities may be absent.

Symptomatic patients

Investigations may include:

  • Blood glucose.
  • Electrolytes.
  • Creatinine and kidney function.
  • Blood gas when respiratory compromise is suspected.
  • Creatine kinase when significant muscle symptoms occur.

Coagulation studies

Coagulopathy is not a characteristic feature of North American coral snake envenomation.

PT/INR, fibrinogen, and platelet measurements may be useful when snake identification is uncertain or an alternative venomous snakebite is possible.

ECG

An ECG may be appropriate in patients with important systemic findings or another clinical indication.

Venom assays

Clinically validated rapid venom assays are not routinely available for U.S. coral snakebite assessment.

14. Current North American coral snake antivenom

Product

North American Coral Snake Antivenin (Equine) is the FDA-licensed antivenom intended for Eastern and Texas coral snake envenomation.

It is manufactured from horse-derived serum globulins raised against Eastern coral snake venom.

Species coverage

The product is intended for:

  • Micrurus fulvius.
  • Micrurus tener.

It is not appropriate for Micruroides euryxanthus based on experimental cross-neutralization data.

Supply situation

Production stopped years ago, and existing supplies have been maintained through FDA-authorized expiration extensions based on stability testing.

Status as of October 2026

The FDA has extended lot CL6814 through December 31, 2026.

The printed expiration date on this lot is June 2022, but FDA authorization extends its usable dating through the specified period.

The FDA states that no alternative coral snake antivenom is currently licensed in the United States.

Practical implication

Clinicians must confirm the current authorization, lot number, storage history, and availability before administration.

Antivenom access should be arranged early, before progressive neurotoxicity develops.

15. Indications for antivenom

Historical approach

Older references recommended administering antivenom after any confirmed Eastern or Texas coral snakebite, even without symptoms.

Current approach

The modern FDA-approved product label specifically advises:

Do not administer antivenom prophylactically to asymptomatic patients.

When antivenom is indicated

Administer appropriate antivenom when clinical evidence of systemic envenomation develops, particularly:

  • New ptosis or diplopia.
  • Progressive neurologic symptoms.
  • Dysarthria.
  • Dysphagia.
  • Difficulty controlling secretions.
  • Generalized weakness.
  • Respiratory muscle weakness.

Early systemic symptoms

Spreading paresthesias or significant myalgia beyond the bite site may precede more obvious neurotoxicity.

These findings warrant immediate toxicology assessment and may support early antivenom treatment.

Important distinction

Pain or tingling confined to the bite site does not automatically justify antivenom.

Nonspecific symptoms such as nausea or headache alone require clinical reassessment rather than automatic treatment.

Clinical principle

Do not administer antivenom indiscriminately, but do not delay it until respiratory failure develops once clinically important neurotoxicity is apparent.

16. Evidence supporting observation rather than prophylactic antivenom

A 2026 retrospective study compared patients with presumed or confirmed Eastern coral snakebites who were initially asymptomatic.

The investigators evaluated outcomes after empiric antivenom versus an observation-based strategy.

Findings

Routine antivenom was not associated with a clear improvement in major clinical outcomes.

Patients treated empirically were more likely to receive intensive-care treatment.

Antivenom-related adverse reactions were clinically important.

Interpretation

The study was observational rather than randomized.

Differences in baseline risk and treatment selection may have influenced the findings.

It also involved relatively few cases requiring intubation.

Clinical conclusion

Current evidence supports closely monitored observation of initially asymptomatic patients, provided that appropriate respiratory support and a plan for antivenom access are available.

This approach must not be confused with early discharge.

17. Antivenom dosing and administration

Antivenom should be administered by clinicians familiar with the product and prepared to treat severe allergic reactions.

Initial dose

The FDA-approved prescribing information recommends:

Adults and adolescents: approximately 3–5 vials intravenously, depending on the clinical response.

The label allows a lower dose in small children according to treatment response.

However, antivenom requirements depend primarily on the venom quantity rather than patient body weight.

Pediatric dosing should therefore be determined with specialist toxicology advice rather than automatically reduced in proportion to weight.

Reconstitution

Each vial is reconstituted with 10 mL of sterile water for injection.

Swirl gently rather than shaking.

Complete dissolution may require approximately 30 minutes.

Intravenous administration

The product is administered intravenously with an appropriate normal-saline infusion.

The label directs clinicians to administer the first 1–2 mL over approximately 3–5 minutes, while observing closely for an allergic reaction.

If tolerated, the remainder is administered at a rate appropriate to the patient’s condition.

The label describes a 250–500 mL saline infusion for adults, with fluid-volume and infusion-rate adjustments in children.

Additional treatment

Further antivenom may be administered if clinically important venom effects persist or progress.

Important correction

The old fixed recommendation of four to six vials, followed automatically by another four to five vials, should be replaced with current product-specific dosing and specialist-directed reassessment.

18. Antivenom hypersensitivity

North American Coral Snake Antivenin contains equine proteins.

Acute hypersensitivity reactions are an important treatment risk.

Acute reactions

These may include:

  • Urticaria.
  • Pruritus.
  • Flushing.
  • Angioedema.
  • Bronchospasm.
  • Hypotension.
  • Anaphylaxis.

Emergency preparedness

Epinephrine and airway equipment must be immediately available.

Anaphylaxis requires prompt standard emergency treatment, including intramuscular epinephrine.

Skin testing

The current FDA label states that clinicians may consider skin testing before administration.

However, skin testing does not reliably exclude anaphylaxis.

It must not delay urgently needed antivenom.

Previous horse-serum reactions

A history of serious equine-protein hypersensitivity increases concern for anaphylaxis.

Nevertheless, when life-threatening envenomation is present, the potential benefits of antivenom may outweigh the risks.

The decision should involve experienced clinicians with the capability to manage severe allergic reactions.

Serum sickness

Delayed serum sickness may occur after treatment.

Typical symptoms include fever, rash, itching, arthralgia, and malaise.

Patients should receive appropriate follow-up instructions for the subsequent 14 days.

19. Texas coral snake envenomation

Texas coral snakebites deserve separate consideration.

A multicenter North American Snakebite Registry study described predominantly mild findings among recorded Micrurus tener envenomations.

Common manifestations

Findings included pain, paresthesias, mild swelling, and redness.

No patients in that series developed clinically significant weakness or respiratory failure.

Antivenom

Antivenom was not administered to patients in the study.

The authors recommended reserving antivenom for objective neurologic weakness or respiratory impairment.

Observation

The study recommended approximately 12–18 hours of monitored observation with appropriate serial neurologic and respiratory assessment.

Interpretation

These findings support a generally lower observed severity compared with Eastern coral snakebite.

However, they do not establish that serious Texas coral snake envenomation is impossible.

The observation period should be individualized through poison-center consultation.

20. Sonoran coral snake envenomation

Micruroides euryxanthus is generally associated with less severe human envenomation.

Most reported bites produce limited local symptoms.

Antivenom

The U.S. North American Coral Snake Antivenin is not indicated for Sonoran coral snake venom.

Management

Treatment generally consists of:

  • Wound care.
  • Analgesia.
  • Appropriate observation.
  • Neurologic and respiratory reassessment when clinically indicated.

Important limitation

A snake identified only as a coral snake should not automatically be treated as a Sonoran species.

Reliable species identification is essential.

21. Other supportive treatment

Analgesia

Acetaminophen or an NSAID may be appropriate for mild pain when not contraindicated.

Avoid unnecessary sedating medications that could obscure neurologic assessment or worsen ventilation.

Fluids

Intravenous fluids should be administered according to clinical need.

Profound hypotension is not typical of uncomplicated coral snake envenomation and requires evaluation for another cause.

Antibiotics

Routine prophylactic antibiotics are not recommended.

Treat established infection or another specific indication when present.

Tetanus

Review immunization status and provide tetanus prophylaxis according to standard wound-care guidance.

Wound procedures

Incision, suction, and injection of fluid beneath the bite site to search for punctures should not be performed.

They do not establish envenomation and may cause additional injury.

22. Observation and hospital admission

Eastern coral snakebite

A conservative contemporary approach is at least 24 hours of monitored observation after a credible Eastern coral snakebite, particularly when antivenom is not immediately available.

Observation should include serial neurologic, bulbar, and respiratory assessments.

Monitoring environment

Patients need access to clinicians capable of recognizing and managing rapid neuromuscular deterioration.

An ICU may be appropriate for significant symptoms or when equivalent monitoring and emergency airway support are unavailable elsewhere.

Texas coral snakebite

Monitored observation of approximately 12–18 hours has been recommended in published registry research, although a longer period may be appropriate according to uncertainty and local protocols.

Symptomatic patients

Patients developing systemic neurologic or respiratory symptoms require hospital admission.

Patients receiving antivenom

Continue monitored observation after administration to ensure symptoms stabilize and to detect immediate adverse reactions or recurrent toxicity.

Discharge

Discharge requires:

  • An adequate species-specific observation period.
  • Stable neurologic and respiratory examinations.
  • No evolving bulbar or respiratory weakness.
  • Reassuring clinical progression.
  • Appropriate specialist approval and follow-up arrangements.

Discharge after only several hours because no fang marks or symptoms are visible is unsafe after a credible Eastern coral snakebite.

23. Expected course and prognosis

Dry bites

Patients who receive little or no venom generally remain asymptomatic and recover without complications.

Mild envenomation

Local discomfort and paresthesias typically resolve without permanent injury.

Significant neurologic envenomation

Symptoms may progress rapidly once neurotoxicity develops.

Antivenom is most useful before substantial neuromuscular injury is established.

Established paralysis

Some patients require prolonged mechanical ventilation despite antivenom.

Recovery from presynaptic nerve-terminal injury may take days or longer.

Mortality

Death is now very uncommon in the United States when appropriate medical care is available.

However, respiratory paralysis can be fatal without timely ventilatory support.

Long-term outcomes

Most survivors recover well.

Persistent complications are uncommon but may occur after prolonged respiratory failure or other severe secondary injury.

24. Pregnancy and breastfeeding

Pregnancy

Information concerning coral snake envenomation during pregnancy is limited.

Maternal respiratory failure, hypoxia, or other serious complications may threaten both the patient and fetus.

Appropriate antivenom should not be withheld solely because of pregnancy when significant envenomation is present.

Obstetric assessment should accompany maternal resuscitation when clinically indicated.

Breastfeeding

Studies examining excretion of North American Coral Snake Antivenin into human milk are lacking.

Because the product contains large antibody proteins, substantial absorption by a breastfed infant is not expected, although direct evidence is limited.

Treatment decisions should consider the mother’s clinical need and the risks of untreated envenomation.

25. Prevention and patient education

Avoid handling

Coral snakes should not be handled, even when they appear small or docile.

Outdoor precautions

Use suitable footwear when walking in habitats where coral snakes occur.

Inspect areas before reaching beneath logs, vegetation, debris, or other concealed spaces.

Snake identification

Do not depend on color-band rhymes.

Maintain distance and seek expert identification when necessary.

After a suspected bite

Every credible coral snakebite requires emergency assessment.

Patients should not wait for weakness or difficulty breathing before seeking care.

Following antivenom

Patients should be instructed to return for fever, rash, joint pain, or other symptoms suggesting serum sickness during the following one to two weeks.

26. Clinical pitfalls

Relying on the red-yellow band rhyme. Color patterns cannot reliably exclude venomous species.

Using outdated taxonomy. The Texas coral snake is Micrurus tener, not simply a subspecies of M. fulvius.

Assuming a coral snake must chew to envenomate. Even a brief bite may deliver venom.

Relying on visible puncture marks. Significant envenomation may occur with little or no visible wound.

Assuming the absence of pain is reassuring. Serious neurotoxicity may occur with minimal local symptoms.

Treating paralysis as universally irreversible. Both presynaptic and postsynaptic toxin effects contribute.

Waiting for low oxygen saturation before assessing ventilation. Hypoventilation may precede hypoxemia.

Delaying intubation for antivenom. Respiratory support takes priority when failure is imminent.

Administering antivenom to every asymptomatic patient. Current product labeling advises against prophylactic use.

Waiting for respiratory failure before giving antivenom to a symptomatic patient. Progressive neurologic or bulbar dysfunction warrants prompt treatment.

Assuming antivenom is readily available. Supply remains limited and requires active coordination.

Using antivenom intended for Eastern and Texas coral snakes against Sonoran coral snake venom. Experimental testing does not support its neutralizing activity.

Following obsolete dosing instructions. Current labeling generally specifies three to five vials initially in adults and adolescents.

Allowing skin testing to delay essential treatment. A negative test cannot reliably rule out anaphylaxis.

Applying pressure immobilization routinely. Current North American first-aid guidelines advise against this practice.

Using suction or venom-extraction devices. These do not provide meaningful benefit and may cause injury.

Discharging an asymptomatic Eastern coral snakebite after only a few hours. Delayed neurotoxicity requires prolonged monitoring.

Assuming the same observation period applies to all three native species. Risk differs between Eastern, Texas, and Sonoran coral snakes.


Key clinical conclusions

North American coral snakebite is primarily a neurotoxic emergency, with delayed neuromuscular paralysis and respiratory failure representing the greatest hazards.

The Eastern coral snake, Micrurus fulvius, presents the most important risk of severe neurotoxicity.

The Texas coral snake, Micrurus tener, generally causes less severe documented envenomation, while the Sonoran coral snake, Micruroides euryxanthus, usually produces limited effects.

Immediate treatment requires appropriate immobilization, emergency assessment, poison-center consultation, and serial neurologic and respiratory examination.

North American Coral Snake Antivenin should be administered when clinically important envenomation develops, rather than prophylactically after every asymptomatic bite.

The antivenom remains in limited supply, with FDA-authorized use of existing lot CL6814 extended through December 31, 2026.

Respiratory support is lifesaving and must never be delayed while waiting for antivenom.

The most important principle is that a patient who initially appears well may develop progressive paralysis hours later.


Image description
0 Comments